Rubicon Research Limited operates as a specialty pharmaceutical company in India, the United States, and internationally. Its primary proprietary technologies for drug delivery comprising RubiSRL for the formulation of sustained release liquids using a combination of ion exchange and membrane diffusion controlled-release technologies; and RubiReten, a gastro-retentive system for drugs with poor solubility and a limited window of absorption. The company develops products in the areas of analgesics/pain management, hypokalemia, gastrointestinal, cardiovascular, skeletal muscle relaxants, metabolic, central nervous system, nicotine replacement therapy, and immunosuppressant. The company was incorporated in 1999 and is based in Mumbai, India.
| Current Price | ₹1,431.35 |
|---|---|
| Market Cap | ₹0 Cr |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Health Care; Pharmaceuticals, Biotechnology and Life Sciences; Pharmaceuticals; Pharmaceuticals; Pharmaceutical Products |
| P/E Ratio | 93.5 |
| 52-Week Range | ₹577.25 – ₹1,527.00 |
| Dividend Yield | 0.10% |
1. Pharmaceutical Products (Generics, Speciality, API, Related Services, Etc.)-100%
RUBICON RESEARCH LIMITED is trading at ₹1,431.35, with a market capitalisation of ₹0 Cr.
RUBICON RESEARCH LIMITED operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Health Care; Pharmaceuticals, Biotechnology and Life Sciences; Pharmaceuticals; Pharmaceuticals; Pharmaceutical Products).
RUBICON RESEARCH LIMITED has a P/E of 93.5.